Scholarlink

Background <p>Mucinous gastric adenocarcinoma (MGC) is a rare, aggressive malignancy. This study aimed to explore whether MGC is associated with poorer survival compared with nonmucinous gastric adenocarcinoma (NMGC) and to further investigate the potential impact of neoadjuvant chemotherapy (NAC) on MGC by assessing overall survival (OS), tumor regression grade (TRG), and histological subtypes.</p> Methods <p>A retrospective analysis was conducted on 492 patients with MGC and 7945 patients with NMGC undergoing resection at Zhejiang Cancer Hospital (2014–2023). Patients were categorized into neoadjuvant and surgery groups. MGC was further classified as pure (≥ 80%) or mixed (&lt; 80%). OS was analyzed using Kaplan–Meier and Cox regression, with propensity score matching (PSM) for adjustment.</p> Results <p>After PSM, OS did not differ between MGC and NMGC. Patients with MGC receiving NAC had significantly worse OS than those undergoing surgery, with NAC as an independent risk factor. TRG analysis showed a markedly lower proportion of responders (TRG 0–1) in MGC than NMGC, indicating reduced chemosensitivity. Among subtypes, NAC remained an adverse factor in pure MGC, while mixed MGC showed no significant difference after PSM.</p> Conclusions <p>MGC exhibits poor pathological response and no survival benefit from NAC, supporting upfront surgery as the preferred approach. TRG findings highlight intrinsic chemoresistance, particularly in pure MGC, underscoring the need for histology-based individualized strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Neoadjuvant Chemotherapy on Prognosis of Patients with Mucinous Gastric Adenocarcinoma: A Propensity Score Matching Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月27日

查看全文
  • Yiming Lu,
  • Danni Zhu,
  • Ke Shen,
  • Jiahui Chen,
  • Xiangdong Cheng

摘要

Background

Mucinous gastric adenocarcinoma (MGC) is a rare, aggressive malignancy. This study aimed to explore whether MGC is associated with poorer survival compared with nonmucinous gastric adenocarcinoma (NMGC) and to further investigate the potential impact of neoadjuvant chemotherapy (NAC) on MGC by assessing overall survival (OS), tumor regression grade (TRG), and histological subtypes.

Methods

A retrospective analysis was conducted on 492 patients with MGC and 7945 patients with NMGC undergoing resection at Zhejiang Cancer Hospital (2014–2023). Patients were categorized into neoadjuvant and surgery groups. MGC was further classified as pure (≥ 80%) or mixed (< 80%). OS was analyzed using Kaplan–Meier and Cox regression, with propensity score matching (PSM) for adjustment.

Results

After PSM, OS did not differ between MGC and NMGC. Patients with MGC receiving NAC had significantly worse OS than those undergoing surgery, with NAC as an independent risk factor. TRG analysis showed a markedly lower proportion of responders (TRG 0–1) in MGC than NMGC, indicating reduced chemosensitivity. Among subtypes, NAC remained an adverse factor in pure MGC, while mixed MGC showed no significant difference after PSM.

Conclusions

MGC exhibits poor pathological response and no survival benefit from NAC, supporting upfront surgery as the preferred approach. TRG findings highlight intrinsic chemoresistance, particularly in pure MGC, underscoring the need for histology-based individualized strategies.